GDTC
CytoMed Therapeutics Limited Ordinary Shares
NASDAQ: GDTC · HEALTHCARE · BIOTECHNOLOGY
$1.00
+0.71% today
Updated 2026-04-30
Market cap
$11.60M
P/E ratio
—
P/S ratio
13.47x
EPS (TTM)
$-0.27
Dividend yield
—
52W range
$1 – $4
Volume
0.0M
CytoMed Therapeutics Limited Ordinary Shares (GDTC) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $44923.00 | $84178.00 | $270335.00 | $290560.00 | $52005.00 | $248269.00 |
| Revenue growth (YoY) | — | — | +87.4% | +221.1% | +7.5% | -82.1% | +377.4% |
| Cost of revenue | — | $3496.00 | $2590.00 | $81034.00 | $2824.00 | $22733.00 | $937821.00 |
| Gross profit | — | $41427.00 | $81587.00 | $-81034.00 | $381922.00 | $52380.00 | $-689552.00 |
| Gross margin | — | 92.2% | 96.9% | -30.0% | 131.4% | 100.7% | -277.7% |
| R&D | $323983.00 | $784199.00 | $806448.00 | $1.13M | $1.20M | $1.43M | $1.70M |
| SG&A | — | $112323.00 | $433474.00 | $443290.00 | $344254.00 | $1.24M | $1.84M |
| Operating income | $-480218.00 | $-1.00M | $-1.40M | $-1.70M | $-3.20M | $-2.63M | $-3.52M |
| Operating margin | — | -2233.0% | -1661.4% | -627.7% | -1101.0% | -5049.8% | -1416.0% |
| EBITDA | $-349624.00 | $-776206.00 | $-1.05M | $-1.10M | $-2.94M | $-1.79M | $-3.34M |
| EBITDA margin | — | -1727.9% | -1244.7% | -405.1% | -1011.1% | -3443.0% | -1346.0% |
| EBIT | $-446849.00 | $-997192.00 | $-1.29M | $-1.39M | $-3.02M | $-1.88M | $-3.52M |
| Interest expense | — | $79711.00 | $87580.00 | $90773.00 | $38180.00 | $15199.00 | $16000.00 |
| Income tax | — | $84709.00 | $-53427.00 | $1189.00 | $486.00 | — | — |
| Effective tax rate | 0.0% | -6.1% | 3.4% | -0.1% | -0.0% | 0.0% | 0.0% |
| Net income | $-632611.00 | $-1.47M | $-1.53M | $-2.27M | $-3.13M | $-1.88M | $-3.05M |
| Net income growth (YoY) | — | -131.9% | -4.6% | -48.0% | -37.9% | +39.9% | -61.8% |
| Profit margin | — | -3266.1% | -1822.3% | -839.9% | -1077.8% | -3621.1% | -1227.1% |